Maternal complications in molecularly confirmed diandric and digynic triploid pregnancies: single institution experience and literature review

Arch Gynecol Obstet. 2020 May;301(5):1139-1145. doi: 10.1007/s00404-020-05515-4. Epub 2020 Mar 26.

Abstract

Objectives: Assessment of the maternal complications in molecularly confirmed diandric and digynic triploid pregnancies.

Methods: Sonographic features, biochemical results, and clinical presentation were analyzed. Beta-hCG level was controlled after diandric triploidy.

Results: The study included nine diandric and twelve digynic triploid pregnancies at the mean gestational age at diagnosis of 14.9 and 18.0 weeks, respectively (p = 0.0391). Mean value of total-hCG was 979 703.6 U/ml in diandric cases and 5 455.4 U/ml in digynic ones (p < 0.000). Maternal complications occurred in 88.9% of diandric triploid pregnancies, including: thecalutein cysts (44.4%), hyperemesis gravidarum (44.4%), symptomatic hyperthyreosis (33.3%), early onset gestational hypertension (22.2%) and vaginal bleeding (11.1%). No case of proteinuria, preeclampsia or HELLP syndrome was observed. Only maternal complication observed in digynic triploidy was vaginal bleeding (50.0%). The mean time of beta-hCG normalization after diandric triploid pregnancies was 84 days (range 11-142 days). No case of gestational trophoblastic neoplasia (GTN) was observed.

Conclusions: Maternal complications (except for vaginal bleeding) are associated with diandric triploidy. The relatively low incidence of hypertensive maternal complications and their less severe course in our cohort may be attributed to the earlier prenatal diagnosis. The frequency of GTN after diandric triploidy may be lower than previously reported.

Keywords: Diandric triploidy; Digynic triploidy; Maternal triploidy; Partial hydatidiform mole; Paternal triploidy; Preeclampsia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adult
  • Female
  • Humans
  • Pregnancy
  • Triploidy*